Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

Completed · Phase 2

Conditions studied: Ovarian Neoplasms

In brief

The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.

Key facts

Study ID

NCT00046800

Run by

Astellas Pharma Inc

People needed

80

Starts

2002-09-01

Expected to finish

2003-03-01

Last updated by the study team

2011-10-20

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed relapsed ovarian cancer.
• Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan).
• One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin.
• At least three weeks since prior chemotherapy and recovery from any related toxicities.
• At least four weeks since prior radiotherapy and recovery from any related toxicities.

Where it is running

• NYU- Kaplan Comprehensive Cancer Center — New York, New York, United States
• The Sarah Cannon Cancer Center, Centennial Medical Center — Nashville, Tennessee, United States
• St Chad's Unit — Birmingham, United Kingdom
• Beatson Oncology Centre — Glasgow, United Kingdom
• Royal Surrey County Hospital — Guildford, Surrey, United Kingdom
• Royal Marsden NHS Trust — London, United Kingdom
• Northern Centre for Cancer Research, Newcastle General Hospital — Newcastle upon Tyne, United Kingdom
• Mount Vernon Hospital — Northwood, Middlesex, United Kingdom
• CRC Department of Medical Oncology — Sutton Surrey, United Kingdom
• Taunton & Somerset Hospital — Taunton, United Kingdom
• Medical Oncology Unit, Torbay District General Hospital — Torquay, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.